The seed for Amplio Pharma was planted when we all worked at Astra Zeneca in Lund, Sweden.
The combination of our different expertises: Marguerite at medac GmbH, market leader for methotrexate therapy and Charlott (pharmacology) and Karin (immunology) laid the foundation for us to develop a modified retention technology that we apply in our NovoBioJect. Here we see a clear opportunity to make a real difference in the lives of patients.
Karin von Wachenfeldt (centre): "I want the patients to feel better so they can fully take back their lives."
Charlott Brunmark (left): "The great thing with NovoBioJect is the retention of long-chain methotrexate-polyglutamates in pro-inflammatory cells. That will amplify the efficacy of methotrexate"
Marguerite Mensonides (right): "With this novel use of novobiocin we have a small molecule that is known to be safe in humans."